

September 11, 2023



# Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, September 28, 2023 at 9:10 a.m. ET.

## Cantor Fitzgerald Global Healthcare Conference:

Date: Thursday, September 28, 2023

Time: 9:10 a.m. ET

Webcast: A live webcast of the fireside chat can be accessed under ["News and Events"](#) on the Investor Relations section of the Mineralys website at [www.mineralystx.com](http://www.mineralystx.com). A replay of the webcast will be available on the Company's website for approximately 90 days.

## About Mineralys

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit <https://mineralystx.com>. Follow Mineralys on [LinkedIn](#) and [Twitter](#).

## Contact:

### Investor Relations

[investorrelations@mineralystx.com](mailto:investorrelations@mineralystx.com)

### Media Relations

Tom Weible

Elixir Health Public Relations

Phone: (1) 515-707-9678

Email: [tweible@elixirhealthpr.com](mailto:tweible@elixirhealthpr.com)



Source: Mineralys Therapeutics, Inc.